On September 4, 2024 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, reported that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences (Press release, Curis, SEP 4, 2024, View Source [SID1234646338]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The H.C. Wainwright 26th Annual Global Investment Conference being held September 9 – 11, 2024. Presentation details are as follows:

Format: Company Presentation
Date: Wednesday, September 11, 2024
Time: 1:00 pm ET
H.C. Wainwright webcast
The 2024 Cantor Fitzgerald Global Healthcare Conference being held September 17 – 19, 2024. Presentation details are as follows:

Format: Fireside Chat
Date: Tuesday, September 17, 2024
Time: 3:05 pm ET
Cantor webcast
Webcasts will be also available on the Curis website at www.curis.com in the ‘Investors’ section.